Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.82 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10155497 | 0.93 | TRPM8 (0.82) | TRPM8MEN1KMT2ASMN1; SMN2TRPV1 | |
| SCHEMBL10155501 | 0.93 | TRPM8 (0.82) | TRPM8MEN1KMT2ASMN1; SMN2TRPV1 | |
| SCHEMBL891564 | 0.91 | TRPM8 (1.00) | TRPM8MEN1KMT2ASMN1; SMN2TRPV1 | |
| SCHEMBL18241124 | 0.91 | TRPM8 (1.00) | TRPM8MEN1KMT2ASMN1; SMN2TRPV1 | |
| SCHEMBL10155482 | 0.91 | TRPM8 (1.00) | TRPM8MEN1KMT2ASMN1; SMN2TRPV1 | |
| SCHEMBL17208068 | 0.91 | TRPM8 (1.00) | TRPM8MEN1KMT2ASMN1; SMN2TRPV1 | |
| SCHEMBL10155511 | 0.88 | TRPM8 (0.84) | TRPM8MEN1KMT2ASMN1; SMN2TRPV1 | |
| SCHEMBL10155510 | 0.86 | TRPM8 (0.77) | TRPM8MEN1KMT2ASMN1; SMN2TRPV1 | |
| SCHEMBL18662582 | 0.86 | TRPM8 (0.77) | TRPM8MEN1KMT2ASMN1; SMN2TRPV1 | |
| SCHEMBL13465300 | 0.85 | TRPM8 (0.82) | TRPM8MEN1KMT2ASMN1; SMN2TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120225871-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120225871-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120083493-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2012-04-05 | — | — | US | disclosed |
| US-20120083493-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2012-04-05 | — | — | US | disclosed |
| US-7772266-B2 | treating or preventing benign prostatic hyperplasia, enlarged prostate, acute urinary retention with 2-Isopropyl-5-methyl-cyclohexanecarboxylic acid (2-amino-2-phenyl-ethyl)-amide; agonists or antagonists of a transient receptor potential proteins; anticarcinogenic agent | DENDREON CORPORATION (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772266-B2 | treating or preventing benign prostatic hyperplasia, enlarged prostate, acute urinary retention with 2-Isopropyl-5-methyl-cyclohexanecarboxylic acid (2-amino-2-phenyl-ethyl)-amide; agonists or antagonists of a transient receptor potential proteins; anticarcinogenic agent | DENDREON CORPORATION (US) | 2010-08-10 | — | — | US | disclosed |
| US-7741355-B2 | Small-molecule modulators of TRP-p8 activity | DENDREON CORPORATION (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741355-B2 | Small-molecule modulators of TRP-p8 activity | DENDREON CORPORATION (US) | 2010-06-22 | — | — | US | disclosed |
| US-20080255185-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255185-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255185-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | TRPC4, TRPC3, TRPC1 | TRPM8 7/4885MEN1 2510/4885KMT2A 4584/4885 |
| US-20120225871-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | TRPC4, TRPC3, TRPC1 | TRPM8 7/4885MEN1 2510/4885KMT2A 4584/4885 |
| US-20120083493-A1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | TRPC4, TRPC3, TRPC1 | TRPM8 7/4885MEN1 2510/4885KMT2A 4584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.